

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: NDA 20-934

Trade Name: LUXIQ Foam, 0.12%

Generic Name:(betamethasone valerate)

Sponsor: Connetics Corporation

Approval Date: February 28, 1999

Indication: Provides for the use of Luxiq (betamethasone valerate) Foam, 0.12%, for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION: NDA 20-934

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tentative Approval Letter				X
Approvable Letter			X	
Final Printed Labeling		X		
Medical Review(s)	X			
Chemistry Review(s)	X			
EA/FONSI			X	
Pharmacology Review(s)	X			
Statistical Review(s)	X			
Microbiology Review(s)	X			
Clinical Pharmacology Biopharmaceutics Review(s)	X			
Bioequivalence Review(s)			X	
Administrative Document(s)	X			
Correspondence	X			

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number:NDA 20-934

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-934

Connetics Corporation
Attention: Claire J. Lockey
Vice President, Regulatory Affairs
3400 West Bayshore Road
Palo Alto, CA 94303

FEB 28 1999

Dear Ms. Lockey:

Please refer to your new drug application (NDA) dated December 16, 1997, received December 17, 1997, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Luxiq™ (betamethasone valerate) Foam, 0.12%.

We acknowledge receipt of your submissions dated January 30, March 26, April 17, July 15, 21 and 27, August 7, September 16 and 22, November 3, 20 and 23, December 1, 8 and 15, 1998; January 19 and 20, February 22(two), and 25, 1999. The user fee goal date for this application is March 17, 1999.

This new drug application provides for the use of Luxiq™ (betamethasone valerate) Foam, 0.12%, for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, and text for the patient package insert, immediate container and carton labels). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 20-934." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitment specified in the facsimile of your letter dated

NDA 20-934

Page 2

February 25, 1999. This commitment, along with the completion date agreed upon, is below.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitment, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to this Phase 4 commitment must be clearly designated "Phase 4 Commitment."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 20-934

Page 3

If you have any questions, please contact Olga Cintron, R. Ph., Project Manager, at (301) 827-2020.

Sincerely,



Jonathan K. Wilkin, M.D.

Director

Division of Dermatologic and Dental Drug Products

Office of Drug Evaluation V

Center for Drug Evaluation and Research

Enclosure